TT-00920
/ TransThera Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
November 18, 2023
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=20 | Completed | Sponsor: TransThera Sciences (Nanjing), Inc. | Recruiting ➔ Completed | N=30 ➔ 20
Enrollment change • Trial completion
February 27, 2023
A Phase 1 Study of TT-00920 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=30 | Completed | Sponsor: TransThera Sciences (Nanjing), Inc. | Recruiting ➔ Completed
Trial completion
February 27, 2023
Phase I, First-In-Human Study of TT-00920 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=42 | Completed | Sponsor: TransThera Sciences (Nanjing), Inc. | Active, not recruiting ➔ Completed | Trial completion date: Nov 2021 ➔ Mar 2022
Trial completion • Trial completion date
May 02, 2022
A Phase 1 Study of TT-00920 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: TransThera Sciences (Nanjing), Inc.
New P1 trial
November 03, 2021
Phase I, First-In-Human Study of TT-00920 in Healthy Subjects
(clinicaltrials.gov)
- P1; N=42; Active, not recruiting; Sponsor: TransThera Sciences (Nanjing), Inc.; Recruiting ➔ Active, not recruiting; N=72 ➔ 42; Trial completion date: Feb 2021 ➔ Nov 2021; Trial primary completion date: Jan 2021 ➔ Jun 2021
Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date
September 14, 2021
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multi Ascending Dose of TT-00920 in Healthy Subjects
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: TransThera Sciences (Nanjing), Inc.
Clinical • New P1 trial
September 17, 2020
[VIRTUAL] TT-00920, a Clinical Stage Novel Phosphodiesterase 9 Inhibitor, Protects Against Heart Failure in a Rat Model of Myocardial Infarction
(AHA 2020)
- P1 | "After 4-week treatment of vehicle, LCZ696, TT-00920, or TT-00920/Valsartan by oral gavage, efficacy was assessed by echocardiography and cardiac histopathology. TT-00920 reversed LAD-induced left ventricular dysfunction and remodeling, supporting its potential as a novel therapeutic agent for heart failure. The superior efficacy of TT-00920/Valsartan combination suggests that TT-00920 and renin-angiotensin-aldosterone system inhibitors may have additive therapeutic effects in heart failure. TT-00920 is currently being evaluated in Phase 1 clinical study for safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers (NCT04364789)."
Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Myocardial Infarction
April 28, 2020
Study of TT-00920 in Healthy Subjects
(clinicaltrials.gov)
- P1; N=72; Recruiting; Sponsor: TransThera Biosciences Co., Ltd
Clinical • New P1 trial • Cardiovascular • Congestive Heart Failure • Heart Failure
1 to 8
Of
8
Go to page
1